Clinical Trial Update: Dose Escalation Study of ZG006 in Participants With Advanced Small Cell Lung Cancer or Neuroendocrine Carcinoma, Followed by Dose Expansion Study in Participants With Neuroendocrine Carcinoma. [Phase 1, Phase 2]

View source ↗

Summary

A dose-escalation and expansion Phase 1/2 trial of ZG006 in neuroendocrine carcinoma and advanced small cell lung cancer is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Neuroendocrine Carcinoma
• Small Cell Lung Cancer

Drugs mentioned

• ZG006

Snippet

Sponsor: Suzhou Zelgen Biopharmaceuticals Co.,Ltd | Conditions: Neuroendocrine Carcinoma | Phase 1, Phase 2 | Status: RECRUITING